Consistent with this, intratumoural administration of AAV8-Syn-SARM1-CDN-eGFP (but not AAV8-Syn-eGFP) suppressed tumour cell proliferation at the intermediate tumour stage but not at the late tumour stage (Extended Data Fig. 6g–k). The gene discussed is SARM1; the disease is neoplasm.